[{"indications": "Indications\u00a0hypertension; heart failure when ACE inhibitors cannot be used, or\r\nin conjunction with an ACE inhibitor when a beta-blocker cannot be\r\nused (see also section 2.5.5); myocardial infarction with\r\nleft ventricular failure or left ventricular systolic dysfunction\r\n(adjunct\u2014see section 2.5.5 and section 2.10.1)", "name": "VALSARTAN With diuretic", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "2 Cardiovascular system", "2.5 Hypertension and heart failure", "2.5.5 Drugs affecting the renin-angiotensin system", "2.5.5.2 Angiotensin-II receptor antagonists", "VALSARTAN", "With diuretic"], "cautions": "Cautions\u00a0\n(From 2.5.5.2 Angiotensin-II receptor antagonists: British National Formulary)\nCautions\u00a0Angiotensin-II receptor antagonists should be used with caution in renal artery stenosis (see also Renal Effects under ACE Inhibitors, section 2.5.5.1). Monitoring of plasma-potassium concentration is advised, particularly in the elderly and in patients with renal impairment; lower initial doses may be appropriate in these patients. Angiotensin-II receptor antagonists should be used with caution in aortic or mitral valve stenosis and in hypertrophic cardiomyopathy. Those with primary aldosteronism, and Afro-Caribbean patients (particularly those with left ventricular hypertrophy), may not benefit from an angiotensin-II receptor antagonist. Interactions: Appendix 1 (angiotensin-II receptor antagonists).", "side-effects": "Side-effects\u00a0see notes above; renal impairment; less\r\ncommonly gastro-intestinal disturbance, syncope, fatigue,\r\ncough, headache, acute renal failure; neutropenia, thrombocytopenia,\r\nmyalgia, and hypersensitivity reactions (including rash, pruritus,\r\nvasculitis, and serum sickness) also reported", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/129035.htm", "doses": ["Hypertension, usually 80\u00a0mg once daily (initially 40\u00a0mg\r\nonce daily in intravascular volume depletion); if necessary increased\r\nat intervals of 4 weeks up to max. 320\u00a0mg daily", "Heart failure, initially 40\u00a0mg twice daily increased at intervals\r\nof at least 2 weeks up to max. 160\u00a0mg twice daily", "Myocardial infarction, initially 20\u00a0mg twice daily increased\r\nover several weeks to 160\u00a0mg twice daily if tolerated", "Name[Co-Diovan\u00ae (Novartis) ] Tablets 80/12.5, orange, f/c, valsartan\r\n80\u00a0mg, hydrochlorothiazide 12.5\u00a0mg, net price 28-tab pack = \u00a313.97\nTablets 160/12.5, red, f/c, valsartan\r\n160\u00a0mg, hydrochlorothiazide 12.5\u00a0mg, net price 28-tab pack = \u00a318.41\nTablets 160/25, brown-orange, f/c,\r\nvalsartan 160\u00a0mg, hydrochlorothiazide 25\u00a0mg, net price 28-tab pack\r\n= \u00a318.41"], "pregnancy": "Pregnancy\u00a0\n(From 2.5.5.2 Angiotensin-II receptor antagonists: British National Formulary)\nPregnancy\u00a0Angiotensin-II receptor antagonists should be avoided in pregnancy unless essential. They may adversely affect fetal and neonatal blood pressure control and renal function; skull defects and oligohydramnios have also been reported."}]